

ASX RELEASE (ASX: MDR)

Sale of shares by Kojent Pty Ltd

Melbourne, Australia, 10 November, 2023 - World-class medication management platform, MedAdvisor Limited (MedAdvisor Solutions or the Company) announces it has been notified that Kojent Pty Ltd (**Kojent**) has sold 6,846,955 shares in the Company to an institutional investor via an on-market crossing.

MedAdvisor Solutions director, Jim Xenos is a director of Kojent and a beneficiary of a trust on behalf of which Kojent holds shares in MedAdvisor.

Prior to the sale, a total of 13,693,911 shares in the Company were held by Kojent on trust for two beneficiaries. Kojent has advised it sold the shares in the Company at the request of the beneficiary which is not otherwise associated with Jim Xenos or the Company. This represents one half of Kojent's holding. Jim Xenos has advised that the remaining shares held by Kojent are beneficially owned by him, and Kojent has no current intention to sell any further shares in the Company.

Mr Xenos said, *"I remain fully committed to the Company and look forward to continuing to support MedAdvisor through this exciting growth phase."*

The share trade has been made in accordance with the Company's Securities Trading Policy. Please see attached Appendix 3Y (Change of Director's Interest Notice) with respect to this change.

- ENDS -

This document has been authorised for release by the Board of MedAdvisor Solutions.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	MEDADVISOR LIMITED
ABN	17 145 327 617

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Jim Xenos
Date of last notice	30 November 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Kojent Pty Ltd (of which Mr Xenos is a director) as trustee of the Kojent Trust (of which Mr Xenos is one of the beneficiaries)
Date of change	8 November 2023
No. of securities held prior to change	Direct: 42,857 fully paid ordinary shares 500,000 unlisted options with expiry date 31 December 2031 Indirect: 13,693,911 fully paid ordinary shares
Class	Fully paid ordinary shares
Number acquired	-

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number disposed	6,846,955
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$1,232,452
No. of securities held after change	Direct: 42,857 fully paid ordinary shares 500,000 unlisted options with expiry date 31 December 2031 Indirect: 6,846,956 fully paid ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market crossing

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest after change	N/A
------------------------------	-----

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	Yes
If so, was prior written clearance provided to allow the trade to proceed during this period?	Yes
If prior written clearance was provided, on what date was this provided?	8 November 2023

+ See chapter 19 for defined terms.